Literature DB >> 2318985

Circulating high molecular weight IgG fibronectin complexes in myeloproliferative disorders.

T P Baglin1, S M Price, B J Boughton.   

Abstract

The plasma of patients with myeloproliferative diseases was examined by polyethylene glycol (PEG) precipitation, analytical ultracentrifugation, and immunoaffinity chromatography for the presence of high molecular weight complexes of IgG and fibronectin. Abnormal circulating high molecular weight material was identified by ultracentrifugation in all patients. This was precipitated by PEG and was shown by exclusion chromatography to contain IgG in a high molecular weight form. Examination of plasma by immunoaffinity chromatography supported previous evidence for complex formation between IgG and fibronectin. These findings are further evidence that abnormal high molecular weight IgG complexes are a prominent feature of myeloproliferative disorders and implicate IgG fibronectin complex formation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2318985      PMCID: PMC502288          DOI: 10.1136/jcp.43.2.102

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  15 in total

1.  Immune complexes in myelofibrosis: a possible guide to management.

Authors:  C M Lewis; G D Pegrum
Journal:  Br J Haematol       Date:  1978-06       Impact factor: 6.998

Review 2.  Fibronectins--adhesive glycoproteins of cell surface and blood.

Authors:  K M Yamada; K Olden
Journal:  Nature       Date:  1978-09-21       Impact factor: 49.962

3.  Enhancement by IgM rheumatoid factor of in vitro ingestion by macrophages and in vivo clearance of aggregated IgG or antigen-antibody complexes.

Authors:  J L Van Snick; E Van Roost; B Markowetz; C L Cambiaso; P L Masson
Journal:  Eur J Immunol       Date:  1978-04       Impact factor: 5.532

4.  Chemical coupling of peptides and proteins to polysaccharides by means of cyanogen halides.

Authors:  R Axén; J Porath; S Ernback
Journal:  Nature       Date:  1967-06-24       Impact factor: 49.962

5.  Purification of fibronectin from human plasma by affinity chromatography under non-denaturing conditions.

Authors:  M Vuento; A Vaheri
Journal:  Biochem J       Date:  1979-11-01       Impact factor: 3.857

6.  Immunologic abnormalities in myelofibrosis with activation of the complement system.

Authors:  B R Gordon; M Coleman; P Kohen; N K Day
Journal:  Blood       Date:  1981-11       Impact factor: 22.113

7.  Idiopathic myelofibrosis: a possible role for immune-complexes in the pathogenesis of bone marrow fibrosis.

Authors:  F C Cappio; R Vigliani; A Novarino; G Camussi; D Campana; F Gavosto
Journal:  Br J Haematol       Date:  1981-09       Impact factor: 6.998

8.  A study of the cellular and humoral immune response in patients with myelofibrosis.

Authors:  E Vellenga; N H Mulder; T H The; H O Nieweg
Journal:  Clin Lab Haematol       Date:  1982

9.  Composition of immune complexes and their relation to plasma fibronectin in chronic myeloproliferative disorders.

Authors:  T P Baglin; A W Simpson; S M Price; B J Boughton
Journal:  J Clin Pathol       Date:  1987-12       Impact factor: 3.411

10.  Receptors for cold-insoluble globulin (plasma fibronectin) on human monocytes.

Authors:  M P Bevilacqua; D Amrani; M W Mosesson; C Bianco
Journal:  J Exp Med       Date:  1981-01-01       Impact factor: 14.307

View more
  2 in total

1.  Hepatic and portal vein-thrombosis.

Authors:  B J Boughton
Journal:  BMJ       Date:  1991-01-26

2.  Lack of binding between cryoimmunoglobulins, immunoglobulins and fibronectin: implications for immune complex vasculitis.

Authors:  D T Brandau; R O'Donnell; V L Kimmel-Truitt
Journal:  Clin Exp Immunol       Date:  1991-01       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.